Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies
As a substrate of P-glycoprotein, levocetirizine should not cause sedative effects. However, while cetirizine, a mixture of levocetirizine and dextrocetirizine, can slightly penetrate the blood brain barrier, the sedative effects of levocetirizine are still under study.
The aim of this study was to investigate the sedative effects of levocetirizine.
An electronic literature search was performed using Medline and EMBASE from January 01, 2001 through August 6, 2015. Randomized controlled trials (RCTs) comparing levocetirizine with other antihistamines or placebo for patients with allergy and healthy subjects were selected. Primary outcome was risk ratio between levocetirizine and comparators. Secondary outcome was change in psychomotor speed. Data were pooled for meta-analysis using a fixed-effect model.
Forty-eight studies of 18,014 patients met the inclusion criteria. When compared to placebo, levocetirizine produced modest sedative effects (RR: 1.67; 95% CI 1.17, 2.38). However, when compared to other second-generation antihistamines, sedative effects of levocetirizine did not differ (RR: 1.23; 95% CI 0.96, 1.58). In subgroup analysis, there was no difference between the sedative effects of levocetirizine and fexofenadine (RR: 1.7; 95% CI 0.59, 4.88), desloratadine (RR: 1.58; 95% CI 0.9, 2.77), loratadine (RR: 1.56; 95% CI 0.28, 8.56), bilastine (RR: 1.17; 95% CI 0.48, 2.84), olopatadine (RR: 1.09; 95% CI 0.81, 1.47), azelastine (RR: 0.19; 95% CI 0.01, 3.68) and rupatadine (RR: 1.47; 95% CI 0.14, 15.72). When compared to first-generation antihistamines, levocetirizine had less sedative effects and less change of reaction time (mean difference: −250.76 s; 95% CI −338.53, −162.98).
Levocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. The sedative effects observed for levocetirizine are not different from other second-generation antihistamines.
KeywordsRisk Ratio Allergic Rhinitis Epworth Sleepiness Scale Cetirizine Loratadine
Kornkiat Snidvongs: conception, development of protocol, study selection, data extraction, assessment of risk of bias, data analysis and interpretation, manuscript preparation. Kachorn Seresirikachorn: search strategy, study selection. Likhit Khattiyawittayakun: data extraction, assessment of risk of bias. Wirach Chitsuthipakorn: conception, development of protocol, critical review, final approval.
Compliance with Ethical Standards
Funding sources for the study
This was an unfunded study.
Authors’ financial disclosures
Kornkiat Snidvongs received honoraria for speaking at symposia for Merck Sharp & Dohme, GlaxoSmithKline, Takeda, Sanofi Aventis.
Kachorn Seresirikachorn, Likhit Khattiyawittayakun, and Wirach Chitsuthipakorn have no conflict of interest.
- 4.De Sutter AI, Saraswat A, van Driel ML. Antihistamines for the common cold. Cochrane Database Syst Rev. 2015;(11):CD009345. doi: 10.1002/14651858.CD009345.pub2.
- 6.Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.cochrane-handbook.org.
- 7.Review Manager (RevMan) [Computer program]. Version 5.1.6 ed. Copenhagen: The Nordic Cochrane Centre. The Cochrane Collaboration; 2011.Google Scholar
- 11.Day JH, Briscoe MP, Rafeiro E, Ratz JD. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the environmental exposure unit (EEU). Int J Clin Pract. 2004;58(2):109–18.CrossRefPubMedGoogle Scholar
- 14.Grant JA, Riethuisen JM, Moulaert B, DeVos C. A double-blind, randomized, single-dose, cross-over comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol. 2002;88(2):190–7. doi: 10.1016/S1081-1206(10)61995-3.CrossRefPubMedGoogle Scholar
- 15.Hindmarch I, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. Curr Med Res Opin. 2001;17(4):241–55. doi: 10.1185/0300799019117011.CrossRefPubMedGoogle Scholar
- 19.Stubner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit—the Vienna challenge chamber (VCC). Curr Med Res Opin. 2004;20(6):891–902. doi: 10.1185/030079904125003700.CrossRefPubMedGoogle Scholar
- 20.Verster JC, de Weert AM, Bijtjes SI, Aarab M, van Oosterwijck AW, Eijken EJ, et al. Driving ability after acute and sub-chronic administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-controlled trial. Psychopharmacology. 2003;169(1):84–90. doi: 10.1007/s00213-003-1462-6.CrossRefPubMedGoogle Scholar
- 24.Horak F, Zieglmayer PU, Zieglmayer R, Kavina A, Lemell P. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol. 2005;60(1):24–31. doi: 10.1111/j.1365-2125.2005.02377.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Potter PC, Paediatric Levocetirizine Study G. Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann Allergy Asthma Immunol. 2005;95(2):175–80. doi: 10.1016/S1081-1206(10)61208-2.CrossRefPubMedGoogle Scholar
- 29.Pasquali M, Baiardini I, Rogkakou A, Riccio AM, Gamalero C, Descalzi D, et al. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. Clin Exp Allergy. 2006;36(9):1161–7. doi: 10.1111/j.1365-2222.2006.02548.x.CrossRefPubMedGoogle Scholar
- 34.Segall N, Gawchik S, Georges G, Haeusler JM. Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Ann Allergy Asthma Immunol. 2010;104(3):259–67. doi: 10.1016/j.anai.2009.12.003.CrossRefPubMedGoogle Scholar
- 35.Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65(4):516–28. doi: 10.1111/j.1398-9995.2009.02217.x.CrossRefPubMedGoogle Scholar
- 37.Hong JB, Lee HC, Hu FC, Chu CY. A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J Am Acad Dermatol. 2010;63(5):e100–2. doi: 10.1016/j.jaad.2010.03.007.CrossRefPubMedGoogle Scholar
- 42.Guilemany JM, Garcia-Pinero A, Alobid I, Centellas S, Marino FS, Valero A, et al. The loss of smell in persistent allergic rhinitis is improved by levocetirizine due to reduction of nasal inflammation but not nasal congestion (the CIRANO study). Int Arch Allergy Immunol. 2012;158(2):184–90. doi: 10.1159/000331329.CrossRefPubMedGoogle Scholar
- 43.Jantarat C, Keskanokwong T. Pharmacokinetic and bioequivalence evaluation of two formulations of levocetirizine 5 mg in healthy Thai volunteers. Thai J Pharm Sci. 2013;37:1–11.Google Scholar
- 46.Mahajan S, Gupta V, Gupta A, Matreja PS, Singh A, Khanna P, et al. Efficacy and safety of azelastine and levocetirizine in allergic rhinitis. J Pak Med Stud. 2013;3(3):143–7.Google Scholar
- 47.Munoz-Cano R, Valero A, Izquierdo I, Sanchez-Lopez J, Domenech A, Bartra J, et al. Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design. Allergy Asthma Clin Immunol. 2013;9(1):43. doi: 10.1186/1710-1492-9-43.CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Takeo T, Kasugai C, Tanaka R, Ando T, Ogawa A, Akita Y, et al. Evaluation of the antihistamine effects of olopatadine and levocetirizine during a 24-h period: a double-blind, randomized, cross-over, placebo-controlled comparison in skin responses induced by histamine iontophoresis. J Dermatol. 2013;40(12):987–92. doi: 10.1111/1346-8138.12326.CrossRefPubMedGoogle Scholar
- 50.Hiraoka K, Tashiro M, Grobosch T, Maurer M, Oda K, Toyohara J, et al. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf. 2015;14(2):199–206. doi: 10.1517/14740338.2015.989831.CrossRefPubMedGoogle Scholar
- 52.Snidvongs K, Rotjanasiriphong C, Phannaso C, Chusakul S, Aeumjaturapat S. Fexofenadine and levocetirizine have equivalent effectiveness for persistent allergic rhinitis. Asian Biomed. 2015;93:1–9.Google Scholar